Fig. 5From: Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trialExpression of immune metagenes in cases with pathologic complete response (pCR) and residual disease (RD) and in pre- and post-treatment samples. a Expression of immune cell type metagenes in cases with pCR and RD. b Expression of immune function metagenes in cases with pCR and RD. c Expression of immune cell type metagenes in pre- and post-treatment samples, in cases with pCR. d Expression of immune cell type metagenes in pre- and post-treatment samples, in cases with RD. e Expression of immune function metagenes in pre- and post-treatment samples in cases with pCR. f Expression of immune function metagenes in pre- and post-treatment samples in cases with RDBack to article page